Fig. 2From: Exploring the feasibility of using the ICER Evidence Rating Matrix for Comparative Clinical Effectiveness in assessing treatment benefit and certainty in the clinical evidence on orphan therapies for paediatric indicationsSelection of orphan therapies for paediatric rare diseases approved by the European Medicines Agency between January 2017 and March 2020Back to article page